Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal vaccine GSK134612 + Cervarix + Boostrix
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
meningococcal vaccine GSK134612 + Cervarix + Boostrix is a co-administration vaccine regimen developed by GSK, specifically evaluated for use in adolescents and young adults. The regimen consists of three distinct vaccine products: GSK134612 (a pentavalent MenABCWY vaccine candidate), Cervarix (a bivalent HPV vaccine), and Boostrix (a Tdap booster). GSK134612 combines the components of the approved vaccines Bexsero and Menveo to provide broad protection against Neisseria meningitidis serogroups A, B, C, W, and Y. Cervarix targets HPV types 16 and 18, which are responsible for the majority of cervical cancers, using the AS04 adjuvant system. Boostrix provides booster immunization against tetanus, diphtheria, and pertussis. This combination approach aims to improve vaccination compliance by reducing the number of clinical visits required to complete the recommended adolescent immunization schedule.
- Other names
- MenABCWY + HPV + Tdapmeningococcal group A, B, C, W-135 and Y vaccine + human papillomavirus vaccine + tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)HPV16 (Human papillomavirus type 16)FHA (Filamentous hemagglutinin)TLR4 (Toll-like receptor 4)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)HPV18 L1Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on meningococcal vaccine GSK134612 + Cervarix + Boostrix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal vaccine GSK134612 + Cervarix + Boostrix.